Several long-term double-blinded, placebo-controlled studies conducted so far with different IFN–1a or IFN–1b formulations have shown their effectiveness in slowing/attenuating the progression and alleviating MS symptoms in patients suffering from numerous forms of this disease. the advantages and limitations of the explained techniques. Despite its limitations, immunomodulation is considered as therapy itself or as an adjunct with encouraging results and developing potential. Keywords:immune system, immunomodulation, inflammation, RNA interference, mesenchymal stem cells, anti-inflammatory, autoimmune diseases, monoclonal antibodies == 1. Introduction == The immune system has an priceless role in the resistance to pathogenic infections and the maintenance of homeostasis. An adequate immune response to an encountered danger is an eligible and a deliberate balance-saving mechanism (14). However, an amplified and Napabucasin out-of-control immune response can act as a self-driving positive opinions loop and can have severe implications and is tightly connected to the development of a wide range of diseases (5,6). Some of them have their source in the chronic inflammatory process, while others result from the buildup of an abnormal immune response against particular cells, thus leading to the development of autoimmune diseases. There is no Napabucasin doubt that this progression of inflammation conduces to disease aggravation and deterioration of patient status. It is legitimate to externally attenuate the immune response because an increasing quantity of evidence indicates that chronic inflammation, manifested, i.e., by an increase in the levels of proinflammatory cytokines, is usually involved in the pathogenesis of many diseases including asthma, rheumatoid arthritis, hepatitis, heart Napabucasin disease, and even some of the most prevalent disorders of the central nervous system (CNS) such as Alzheimers disease, epilepsy, depressive disorder, and schizophrenia. Immunomodulation is usually a potent branch, with a Mouse monoclonal to PRAK steady progress in pharmacokinetics and pharmacodynamics. There are numerous difficulties that need to be confronted such as attenuation of the side effects in pharmacological treatment (7,8) or toxicity in the newest interventions (9). However, so far, immunomodulation is usually successfully applied in the medical center (10,11). The immune system is usually a multiscale system that involves genes, molecules, cells, and organs, organized in complex networks of synergistic interactions and aimed at combating various types of threats to the organism (12). Our systematically expanding knowledge about this complex network has enabled us to more selectively influence its individual components, allowing a more effective treatment of many diseases. For example, in oncology, it is possible to enhance the natural ability of human T cells to recognize tumor cells (11,13). The paracrine anti-inflammatory properties of mesenchymal stem cells (MSCs) are used in the treatment of some diseases (explained further in a subsection in this article). Another possibility is usually to inactivate specific proinflammatory factors (i.e., TNF-, IL-6) using monoclonal antibodies (14,15). This clinical branch also benefits from novel methods of antibody design and production (16,17). Monoclonal antibodies can be also used as agonists to imitate immunomodulatory signaling on antigen-presenting cells. We also can inhibit proinflammatory factors by blocking their release (1820). There is also a wide range of pharmaceuticals modulating inflammasome functioning (21,22). Also, well-established immunomodulatory therapies, such as corticosteroids, non-steroidal anti-inflammatory drugs, histamine antagonists, and interferons, have a new face in the context of research aiming to improve their efficiency. In brief, there are various potential targets in immunomodulatory intervention which efficiently modulate the immune response at its many stages. Immunomodulation, based on our knowledge about immunity, has not yet been fully explored but constitutes a perfect tool or an adjunct to regulate some disease progression. In this review, we expose the mechanisms of immunity and immunomodulation strategies used in basic science and in the medical center. Immunomodulation strategies are explained cross-sectionally starting from well-established pharmaceutical interventions, through biological strategies, to the most recent scientific achievements as genome editing and regenerative medicine tools. == 2. Innate immune response == Innate immunity is Napabucasin the first line of defense against pathogens. This kind of immune response is not selective and does not result in immune memory; however, it is quick in reaction. It entails epithelial barriers and phagocytes, which are a group of myeloid cells, composed of neutrophils, dendritic cells, blood monocytes, and tissue macrophages. The innate immune response entails also the match system, natural killer (NK) cells, and tissue-resident immune cells (23). An example of the regulation of this type of immunity is usually paracrine secretion of residual MSCs, which can modulate the functions of tissue macrophages, which is usually discussed further in.